Neurocrine Biosciences appoints new CEO with revised compensation

SAN DIEGO, CA - Neurocrine (NASDAQ:NBIX) Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company, announced today the appointment of Kyle Gano, Ph.D., as President and Chief Executive Officer effective immediately. The transition comes with an amended and restated employment agreement that includes a revised compensation package.

Dr. Gano, whose leadership role commenced today, will receive an annual base salary of $900,000. He is also eligible for an annual cash incentive bonus, with an initial target amount equal to 100% of his base salary. The promotion includes equity grants under the company's 2020 Equity Incentive Plan.

Dr. Gano will be granted stock options valued at approximately $750,000, restricted stock units (RSUs) worth about $300,000, and performance-vesting restricted stock units (PRSUs) valued around $450,000. The stock options and RSUs will vest over a four-year period, while the PRSUs will vest based on the achievement of performance goals set in March 2024.

The employment agreement stipulates severance benefits in case of an "involuntary termination," contingent upon the execution of a customary release of claims in favor of Neurocrine Biosciences. If Dr. Gano's employment is terminated without "cause" or if he resigns for "good reason" outside of a change in control period, he will be entitled to severance pay equal to 1.5 times the sum of his annual salary and target bonus, among other benefits. Within the change in control period, the severance pay increases to twice that sum, with additional benefits.

In the event of termination due to death or "disability," Dr. Gano's equity awards would fully vest, with the level of performance-vesting equity awards determined by the Compensation Committee.

Neurocrine Biosciences specializes in neurological and endocrine-related diseases and disorders. The company's updated executive compensation arrangements reflect its commitment to aligning the interests of its leadership with those of its shareholders.

This announcement is based on the latest 8-K filing with the Securities and Exchange Commission. The details provided are intended to give shareholders and the market an understanding of the new CEO's compensation structure and the company's strategic direction under his leadership.

In other recent news, Neurocrine Biosciences has seen significant developments. The company reported over 30% year-over-year growth in sales of their drug, INGREZZA, leading to an increase in their sales guidance for the year to a range of $2.25 billion to $2.3 billion. On the other hand, the company decided to halt the development of its drug luvadaxistat, which was being studied for cognitive impairment associated with schizophrenia, due to inconsistent results in the ERUDITE Phase 2 clinical study.

Analysts from Raymond James resumed coverage of Neurocrine Biosciences with an Outperform rating, setting a price target of $155. The firm sees potential in the company's product Ingrezza and the Congenital Adrenal Hyperplasia (CAH) market.

However, Mizuho maintained a Neutral rating on Neurocrine Biosciences, pointing out warnings on the label of Bristol Myers (NYSE:BMY) Squibb's schizophrenia drug, Cobenfy.

Despite this, Piper Sandler upgraded the company's stock from Neutral to Overweight, expressing confidence in the company's investigational drug NBI-1117568.

Neurocrine Biosciences also showed sustained improvements in the treatment of Huntington's disease chorea with INGREZZA capsules according to interim results from the KINECT-HD2 study. Meanwhile, BMO Capital Markets maintained a Market Perform rating for Neurocrine, following the discontinuation of luvadaxistat's development. These are the recent developments in the ongoing story of Neurocrine Biosciences.

InvestingPro Insights

As Neurocrine Biosciences (NASDAQ:NBIX) transitions to new leadership under Dr. Kyle Gano, investors may find additional context from recent financial data and expert analysis valuable. According to InvestingPro, NBIX has demonstrated strong financial performance with a revenue growth of 26.69% over the last twelve months as of Q2 2024, reaching $2.12 billion. This robust growth is complemented by a healthy gross profit margin of 68.55% for the same period.

InvestingPro Tips highlight that NBIX is expected to see net income growth this year, which aligns with the company's decision to implement a performance-based compensation structure for its new CEO. Additionally, the company operates with a moderate level of debt and has liquid assets exceeding short-term obligations, suggesting financial stability as it enters this new phase of leadership.

For investors considering NBIX's valuation in light of this executive change, it's worth noting that the stock is trading at a low P/E ratio relative to near-term earnings growth, with a PEG ratio of 0.37 as of Q2 2024. This could indicate potential undervaluation, especially considering the company's profitability over the last twelve months and analysts' predictions of continued profitability this year.

These insights are just a snapshot of the comprehensive analysis available on InvestingPro, which offers 11 additional tips for NBIX, providing a more thorough understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.